Total Payments
$99,716
2024 Payments
$149.99
Companies
18
Transactions
100
Payment Breakdown by Category
Consulting$57,623 (57.8%)
Other$28,280 (28.4%)
Research$7,247 (7.3%)
Food & Beverage$3,607 (3.6%)
Travel$2,918 (2.9%)
Education$40.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $57,623 | 35 | 57.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $14,030 | 1 | 14.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,900 | 4 | 9.9% |
| Unspecified | $7,247 | 8 | 7.3% |
| Honoraria | $4,350 | 3 | 4.4% |
| Food and Beverage | $3,607 | 39 | 3.6% |
| Travel and Lodging | $2,918 | 9 | 2.9% |
| Education | $40.00 | 1 | 0.0% |
Payments by Type
General
$92,469
92 transactions
Research
$7,247
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $42,597 | 29 | $0 (2022) |
| Astute Medical, Inc. | $14,850 | 6 | $0 (2018) |
| Quidel Corporation | $10,232 | 6 | $0 (2023) |
| Alere Inc. | $7,000 | 6 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $6,970 | 9 | $0 (2019) |
| Relypsa, Inc. | $5,805 | 13 | $0 (2019) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $3,950 | 9 | $0 (2020) |
| Amgen Inc. | $2,975 | 1 | $0 (2020) |
| Brahms GmbH | $1,846 | 1 | $0 (2018) |
| Beckman Coulter, Inc. | $1,389 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $149.99 | 1 | Philips North America LLC ($149.99) |
| 2023 | $4,531 | 4 | Quidel Corporation ($4,400) |
| 2022 | $2,177 | 5 | Abbott Laboratories ($1,856) |
| 2021 | $27,505 | 6 | Abbott Laboratories ($27,505) |
| 2020 | $8,738 | 10 | Abbott Laboratories ($3,016) |
| 2019 | $18,198 | 35 | Merck Sharp & Dohme Corporation ($6,970) |
| 2018 | $19,843 | 25 | Abbott Laboratories ($5,445) |
| 2017 | $18,574 | 14 | Astute Medical, Inc. ($9,900) |
All Payment Transactions
100 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/07/2024 | Philips North America LLC | (CK4) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $149.99 | General |
| Category: Medical Device | ||||||
| 10/12/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $31.18 | General |
| Category: Hyperkalemia | ||||||
| 05/11/2023 | Quidel Corporation | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 04/13/2023 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $100.00 | General |
| Category: Cardiology | ||||||
| 01/25/2023 | Quidel Corporation | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 12/22/2022 | Abbott Laboratories | CARDIOMEMS (Device) | Consulting Fee | Cash or cash equivalent | $1,856.00 | General |
| Category: Heart Failure | ||||||
| 11/18/2022 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $71.18 | General |
| Category: Hyperkalemia | ||||||
| 10/01/2022 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $129.78 | General |
| Category: Hyperkalemia | ||||||
| 09/30/2022 | PFIZER INC. | VYNDAMAX (Drug) | Food and Beverage | In-kind items and services | $81.49 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/26/2022 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $38.29 | General |
| Category: Hyperkalemia | ||||||
| 11/18/2021 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $2,320.00 | General |
| Category: Heart Failure | ||||||
| 11/10/2021 | Abbott Laboratories | Architect i2000SR Analyser System (Device) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $14,030.00 | General |
| Category: Core Diagnostics | ||||||
| 10/27/2021 | Abbott Laboratories | Architect i2000SR Analyser System (Device) | Consulting Fee | Cash or cash equivalent | $4,640.00 | General |
| Category: Core Diagnostics | ||||||
| 04/08/2021 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $6,032.00 | General |
| Category: Heart Failure | ||||||
| 03/26/2021 | Abbott Laboratories | Architect (Device) | Travel and Lodging | In-kind items and services | $19.28 | General |
| Category: Core Diagnostics | ||||||
| 02/04/2021 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $464.00 | General |
| Category: Heart Failure | ||||||
| 12/17/2020 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $1,392.00 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 12/16/2020 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,975.00 | General |
| 09/30/2020 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | In-kind items and services | $614.00 | Research |
| Study: LCH-PO-98755 SEX-BASED DIFFERENCES IN BIOMARKERS QUALITY OF LIFE & REVERSE CARDIAC REMODELING IN PATIENTS WITH HFREF TREATED WITH SACUBITRIL/VALSARTAN • Category: CARDIOVASCULAR | ||||||
| 09/30/2020 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | In-kind items and services | $614.00 | Research |
| Study: LCH-PO-98754 RACIAL AND ETHNIC DIFFERENCES IN NT-PROBNP CONCENTRATIONS AND REVERSE CARDIAC REMODELING IN PATIENTS WITH SYSTOLIC HEART FAILURE • Category: CARDIOVASCULAR | ||||||
| 09/30/2020 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | In-kind items and services | $519.00 | Research |
| Study: LCH-PO-98830 ATRIAL NATRIURETIC PEPTIDE MEDIATES REVERSE CARDIAC REMODELING DURING TREATMENT WITH SACUBITRIL/VALSARTAN IN PATIENTS WITH HFREF • Category: CARDIOVASCULAR | ||||||
| 07/21/2020 | Beckman Coulter, Inc. | DXI 800 (Device) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: IMMUNOASSAY | ||||||
| 06/25/2020 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $464.00 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 03/05/2020 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $464.00 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 03/05/2020 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $232.00 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ANTERES HF RENAMED | Alere Inc. | $2,000 | 2 |
| Alere NT pro BNP | Alere Inc. | $2,000 | 2 |
| Alere NT ProBNP for ARCHITECT | Alere Inc. | $1,500 | 1 |
| LCH-PO-98754 RACIAL AND ETHNIC DIFFERENCES IN NT-PROBNP CONCENTRATIONS AND REVERSE CARDIAC REMODELING IN PATIENTS WITH SYSTOLIC HEART FAILURE | NOVARTIS PHARMACEUTICALS CORPORATION | $614.00 | 1 |
| LCH-PO-98755 SEX-BASED DIFFERENCES IN BIOMARKERS QUALITY OF LIFE & REVERSE CARDIAC REMODELING IN PATIENTS WITH HFREF TREATED WITH SACUBITRIL/VALSARTAN | NOVARTIS PHARMACEUTICALS CORPORATION | $614.00 | 1 |
| LCH-PO-98830 ATRIAL NATRIURETIC PEPTIDE MEDIATES REVERSE CARDIAC REMODELING DURING TREATMENT WITH SACUBITRIL/VALSARTAN IN PATIENTS WITH HFREF | NOVARTIS PHARMACEUTICALS CORPORATION | $519.00 | 1 |
About Dr. Alan Maisel, MD
Dr. Alan Maisel, MD is a Cardiovascular Disease healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851485767.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Maisel, MD has received a total of $99,716 in payments from pharmaceutical and medical device companies, with $149.99 received in 2024. These payments were reported across 100 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($57,623).
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location San Diego, CA
- Active Since 10/03/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1851485767
Products in Payments
- CardioMEMS HF System (Device) $22,052
- Architect i2000SR Analyser System (Device) $18,670
- NephroCheck Test (Device) $9,900
- Triage (Device) $8,200
- Veltassa (Drug) $6,075
- Nephrocheck (Device) $4,950
- ENTRESTO (Drug) $3,950
- CARDIOMEMS (Device) $1,856
- PCT (Device) $1,846
- DXI 800 (Device) $1,000
- WATCHMAN (Device) $630.35
- Product in Development (Device) $600.00
- (CK4) MCOT (Device) $149.99
- Assure WCD (Device) $100.00
- GENERAL TACHY (Device) $100.00
- LifeVest (Device) $100.00
- VYNDAMAX (Drug) $81.49
- CD cobas Reagents (Device) $68.73
- Architect (Device) $19.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in San Diego
Jonathan Hsu, Md, MD
Cardiovascular Disease — Payments: $1.1M
Cardiovascular Disease $1.1M
Dr. Raghava Gollapudi, M.d, M.D
Cardiovascular Disease — Payments: $572,162
Cardiovascular Disease $572,162
Dr. Hirsch Mehta, Md, MD
Cardiovascular Disease — Payments: $527,825
Cardiovascular Disease $527,825
Dr. Barry Greenberg, M.d, M.D
Cardiovascular Disease — Payments: $463,770
Cardiovascular Disease $463,770
Dr. Mitul Patel, M.d, M.D
Cardiovascular Disease — Payments: $459,569
Cardiovascular Disease $459,569
Dr. Ulrika Birgersdotter-Green, Md, MD
Cardiovascular Disease — Payments: $430,713
Cardiovascular Disease $430,713